Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatological Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynaecological Cancers
Haematological Malignancies
Haematology
Head and Neck Cancer
Immunotherapy
Leukaemia
Lung Cancer
Lymphoma
Multiple Myeloma
Endocrine Cancers
Ovarian Cancer
Pancreatic Cancer
Paediatric Oncology
Policy
Prostate Cancer
Renal Cancer
Sarcoma
Supportive Cancer Care
Soft Tissue Tumours
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 21, Issue 1, 2025

We are delighted to present the latest edition of touchREVIEWS in Oncology & Haematology. This issue underscores the evolving landscape of cancer therapeutics, showcasing advances across a wide range of malignancies, from haematologic diseases to solid tumours, through novel mechanisms, emerging biomarkers and personalized treatment strategies. We begin with an editorial by Isabela Wen-Chi Chang […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin

Search Results

Showing Results for olutasidenib,

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

Foreword - touchREVIEWS in Oncology & Haematology, Volume 20, Issue 1, 2024

Axel S Merseburger

Welcome to the latest issue of touchREVIEWS in Oncology & Haematology. We are honoured to present a series of compelling articles that reflect cutting-edge developments and diverse perspectives in this ever-evolving field. This issue includes a series of editorials and ...
Mark CompleteCompleted
BookmarkBookmarked

Olutasidenib for Adults with Relapsed or Refractory Acute Myeloid Leukaemia with Isocitrate Dehydrogenase 1 Mutation

Florence Pasquier, Stéphane De Botton

Key points Olutasidenib induces durable responses in patients with relapsed or refractory (R/R) acute myeloid leukaemia (AML) with isocitrate dehydrogenase 1 (IDH1) mutations in the phase I and II clinical trials. The side effects of olutasidenib are well known and ...

touchREVIEWS in Oncology & Haematology. 2024;20(1):25–31
Developed by Touch
Coverage from: ASH Highlights

Jorge Cortes, ASH 2022: IDH1 inhibitors in the treatment of IDH1-mutant acute myeloid leukaemia - results from a phase II pivotal clinical trial

View Coverage

Latest articles videos and clinical updates - straight to your inbox

Close Popup